Prescribing GLP-1 receptor agonists

Published Last updated See all updates

Glucagon-like peptide-1 (GLP-1) receptor agonist availability is resolved. Supply content is maintained by DHSC.

About medicines supply advice · Advice generated by DHSC

This page was prepared and is being maintained by SPS on behalf of the Department of Health and Social Care Medicine Supply Team (DHSC).

Prescribing advice

The supply for GLP-1 RA has largely improved with all strengths and presentations of semaglutide and dulaglutide now available.

Prescribers should consider prescribing GLP-1 RAs for patients within their licensed indications and in line with the relevant NICE guidelines.

Patients concerned about their current treatment, or who have questions about accessing these medicines, should contact their prescriber in the first instance.

NICE guidance

Prescribing advice is available from the following key resources:

Further advice

Medicines Supply Tool

Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.

Update history

  1. Updated as supply for GLP-1 RA has largely improved.
  1. Updated to reflect publication of the MSN on 18 March 2024.
  1. Ozempic 0.5mg solution for injection in pre-filled pen is out of stock.
  1. Rybelsus supply position clarified.
  1. Link to the updated NatPSA published 3 Jan 2024; link to NG28 updated and link to CG189 has been added.
  1. Shortage of Byetta 10micrograms/0.04mL solution for injection 1.2mL pre-filled pens added.
  1. Product details and link to further information added for Wegovy. Status changed from intermittent to limited availability for other GLP-1 RAs.
  1. Content updated to reflect the publication of the NatPSA and Saxenda supply issue added.
  1. Bydureon has been added to the exenatide section.
  1. Published

Print this page